Long-Term Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reduces Arterial FDG Uptake

JACC Cardiovasc Imaging. 2019 Dec;12(12):2573-2574. doi: 10.1016/j.jcmg.2019.09.024.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Anticholesteremic Agents / administration & dosage*
  • Aorta / diagnostic imaging
  • Aorta / drug effects*
  • Aorta / metabolism
  • Aortic Diseases / blood
  • Aortic Diseases / diagnostic imaging
  • Aortic Diseases / drug therapy*
  • Biomarkers / blood
  • Carotid Arteries / diagnostic imaging
  • Carotid Arteries / drug effects*
  • Carotid Arteries / metabolism
  • Carotid Artery Diseases / blood
  • Carotid Artery Diseases / diagnostic imaging
  • Carotid Artery Diseases / drug therapy*
  • Cholesterol, LDL / blood
  • Drug Administration Schedule
  • Dyslipidemias / blood
  • Dyslipidemias / diagnosis
  • Dyslipidemias / diagnostic imaging*
  • Female
  • Fluorodeoxyglucose F18 / administration & dosage
  • Greece
  • Humans
  • Inflammation Mediators / blood
  • Male
  • Middle Aged
  • PCSK9 Inhibitors*
  • Positron Emission Tomography Computed Tomography
  • Predictive Value of Tests
  • Prospective Studies
  • Radiopharmaceuticals / administration & dosage
  • Time Factors
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Anticholesteremic Agents
  • Biomarkers
  • Cholesterol, LDL
  • Inflammation Mediators
  • PCSK9 Inhibitors
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • PCSK9 protein, human
  • evolocumab
  • alirocumab